Hematopoietic and lymphoid system neoplasm

Summary

Hematopoietic and lymphoid system neoplasm (MONDO:0002334) is a cancer (an umbrella term covering 9 Mondo subtypes) and 627 clinical trials. Top therapeutic interventions include filgrastim, fedratinib, and 2-mercaptoethanesulfonic acid. A subtype of neoplasm — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Umbrella term: 9 Mondo subtypes
• Clinical trials: 627

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	hematopoietic and lymphoid system neoplasm
Mondo ID	MONDO:0002334
MeSH	D019337
DOID	DOID:2531
NCIT	C35813
SNOMED CT	129154003
UMLS	C1512393
MedGen	268180
GARD	0023120
Anatomy (UBERON)	UBERON:0002390
Is cancer (heuristic)	yes

Also known as: blood cancer · blood neoplasm (disease) · blood tumor · blood tumour · haematological tumours · haematopoietic and lymphoid system tumour · haematopoietic cancer · haematopoietic neoplasm · haematopoietic neoplasm (morphologic abnormality) · haematopoietic system neoplasm · haematopoietic system tumour · haematopoietic tumours · hematologic malignancy · hematologic neoplasm · hematopoietic and lymphoid system neoplasm · hematopoietic and lymphoid system tumor · hematopoietic cancer · hematopoietic neoplasm · hematopoietic neoplasm (morphologic abnormality) · hematopoietic system neoplasm (+11 more)

Disease family

This is a subtype of neoplasm. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › hematopoietic and lymphoid system neoplasm

Related subtypes (47): pre-malignant neoplasm, endocrine gland neoplasm, giant cell tumor, skin neoplasm, mesenchymal cell neoplasm, epidural spinal canal neoplasm, skeletal muscle neoplasm, trophoblastic neoplasm, cancer, germ cell tumor, benign neoplasm, upper aerodigestive tract neoplasm, histiocytoma, embryonal neoplasm, head and neck neoplasm, epithelial neoplasm, reproductive system neoplasm, non-seminomatous lesion, odontogenic cyst, phosphaturic mesenchymal tumor, thyroglossal duct cyst, hamartoma, mesenchymoma, mesothelial neoplasm, peritoneal neoplasm, virus associated tumor, nail tumor, respiratory tract neoplasm, spindle cell neoplasm, mixed neoplasm, urinary system neoplasm, cystic neoplasm, childhood neoplasm, melanocytic neoplasm, digestive system neoplasm, nervous system neoplasm, neoplasm of thorax, connective tissue neoplasm, bronchial adenomas/carcinoids childhood, diffuse idiopathic pulmonary neuroendocrine cell hyperplasia, erythroplakia, retroperitoneal neoplasm, cardiovascular neoplasm, dermoid or epidermoid cyst of the central nervous system, connective and soft tissue neoplasm, NTRK fusion positive cancer, RET fusion positive cancer

Subtypes (9): cavernous hemangioma, thymus neoplasm, bone marrow neoplasm, STAT3-related early-onset multisystem autoimmune disease, myeloid hemopathy, lymphoid hemopathy, lymph node neoplasm, spleen neoplasm, hematopoietic and lymphoid cell neoplasm

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

0 approved, 4 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Methylprednisolone	Phase 3 (in late-stage trials)
Piperacillin	Phase 3 (in late-stage trials)
Tazobactam	Phase 3 (in late-stage trials)
Tranexamic Acid	Phase 3 (in late-stage trials)

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Acalabrutinib, Alemtuzumab, Atezolizumab, Azacitidine, Bendamustine, Bortezomib, Busulfan, Cefepime, Cholecalciferol, Cilastatin, Crisantaspase, Cyclosporine, Cytarabine, Daptomycin, Dexamethasone, Doxorubicin, Duvelisib, Elotuzumab, Erlotinib, Etoposide, Filgrastim, Fludarabine, Fludarabine Phosphate, Ibrutinib, Inotuzumab Ozogamicin, Itacitinib, Ixazomib, Lenalidomide, Linezolid, Maraviroc, Melphalan, Meropenem, Methotrexate, Mycophenolate Mofetil, Nivolumab, Panobinostat, Pembrolizumab, Platelet Concentrate, Plerixafor, Prednisone, Rituximab, Ruxolitinib, Sargramostim, Tacrolimus Anhydrous, Thiotepa, Tocilizumab, Ustekinumab, Vancomycin, Venetoclax, Vincristine.

Clinical trials & evidence

Clinical trials

Clinical trials: 627.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	291
PHASE1	114
PHASE2	109
PHASE1/PHASE2	56
PHASE3	29
EARLY_PHASE1	17
PHASE4	7
PHASE2/PHASE3	4

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06582186	PHASE4	NOT_YET_RECRUITING	Individualized First Maintenance Doses of Voriconazole Through a Multiparametric Algorithm
NCT07590648	PHASE4	NOT_YET_RECRUITING	Early Discontinuation of Antibiotics in Paediatric High-risk Febrile Neutropenia
NCT00067730	PHASE4	COMPLETED	A Safety Evaluation of Drotrecogin Alfa (Activated) in Patients With Blood Cancer, Severe Infection Related to Bone Marrow Transplantation
NCT02895529	PHASE4	TERMINATED	A Study Comparing the Efficacy of Intravenous Followed by Oral Itraconazole With Intravenous Caspofungin For Empiric Antifungal Therapy in Neutropenic Participants With Hematological Malignancy
NCT03908138	PHASE4	UNKNOWN	RDD Versus VDD in Newly Diagnosed Patients With Multiple Myeloma
NCT04673175	PHASE4	TERMINATED	Ceftolozane-Tazobactam for Directed Treatment of Pseudomonas Aeruginosa Bacteremia and Pneumonia in Patients With Hematological Malignancies and Hematopoietic Stem Cell Transplantation
NCT04952766	PHASE4	COMPLETED	Study Evaluating SARS-CoV-2 (COVID-19) Humoral Response After BNT162b2 Vaccine in Immunocompromised Adults Compared to Healthy Adults
NCT03486873	PHASE3	RECRUITING	Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
NCT04409236	PHASE3	ACTIVE_NOT_RECRUITING	Quit2Heal Smartphone App in Helping Cancer Patients Quit Smoking
NCT04448184	PHASE3	RECRUITING	Platelet Transfusions in Hematopoietic Stem Cell Transplantation (The PATH III Trial)
NCT06169267	PHASE3	ACTIVE_NOT_RECRUITING	Passive Music Intervention for the Reduction of Anxiety in Patients Undergoing Bone Marrow Aspiration and/or Biopsy
NCT06278896	PHASE3	NOT_YET_RECRUITING	Early Neutropenic Fever De-escalation of Antibiotics Study
NCT06378138	PHASE2/PHASE3	RECRUITING	ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (APEX-03)
NCT06401356	PHASE3	RECRUITING	An Extension Study for Patients Previously Enrolled in Studies With Pelabresib
NCT06449586	PHASE3	ACTIVE_NOT_RECRUITING	CMV-specific T Cell Immunity Test Indicated Prophylaxis of Letermovir After All-HSCT
NCT07186192	PHASE3	RECRUITING	Digital Health Intervention for Self-Management and Telemonitoring in Chimeric Antigen Receptor (CAR-T) Therapy
NCT07485855	PHASE3	RECRUITING	Influenza Vaccination Strategy for Patients With Hematologic Malignancy
NCT07511127	PHASE3	RECRUITING	Comparing the Efficacy of Different Durations of Maribavir Treatment Regimens in Allo-HSCT
NCT00044759	PHASE3	COMPLETED	Study Comparing the Safety and Efficacy of Piperacillin/Tazobactam to Cefepime in Patients With Hematologic Malignancy or Lymphoma
NCT00138112	PHASE3	COMPLETED	Trial of Prophylactic Versus Empirical Vancomycin for the Prevention of Streptococcal Sepsis After Hematopoietic Cell Transplantation
NCT00165282	PHASE2/PHASE3	COMPLETED	Mindfulness Meditation in Bone Marrow Transplantation
NCT00469729	PHASE2/PHASE3	COMPLETED	Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy
NCT00750737	PHASE3	COMPLETED	Oral Posaconazole Three Times Per Day vs Weekly High Dose Amphotericin B Lipid Complex (ABLC)
NCT01217723	PHASE3	UNKNOWN	Thymoglobulin in Unrelated Hematopoietic Progenitor Cell Transplantation
NCT01237639	PHASE3	COMPLETED	Study of Red Blood Cell Transfusion Triggers in Patients Undergoing Hematopoietic Stem Cell Transplantation
NCT01345019	PHASE3	COMPLETED	Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Patients With Multiple Myeloma
NCT01437787	PHASE3	COMPLETED	Phase III Study of SAR302503 in Intermediate-2 and High Risk Patients With Myelofibrosis
NCT02623309	PHASE3	COMPLETED	Studyof Allogeneic Hematopoietic Stem Cell Transplantation From One Haplotype Mismatch Related Donor or From an Unrelated Donor in Elderly Patients
NCT02635984	PHASE3	COMPLETED	Study of FOND Versus FOND+O for the Prevention of CINV in Hematology Patients Receiving Highly Emetogenic Chemotherapy Regimens
NCT02650791	PHASE3	COMPLETED	Platelet Transfusion Requirements in Hematopoietic Transplantation Pilot Study
NCT02696408	PHASE3	COMPLETED	Efficacy of Prophylactic Low Level Laser Therapy (LLLT) Performed by Nurses for Decreasing Severity of Oral Mucositis During Hematopoietic Stem Cell (HSC) Transplantation
NCT02944045	PHASE3	UNKNOWN	Effect of Steroids During Pneumocystis Infection Among Non HIV Immunocompromised Patients
NCT03136445	PHASE3	COMPLETED	TRial to EvaluAte Tranexamic Acid Therapy in Thrombocytopenia
NCT03483194	PHASE2/PHASE3	COMPLETED	Therapeutic Virtual Reality : Impact on the Management of Pain and Anxiety Related to Hematology Care (REVEH)
NCT03800758	PHASE3	COMPLETED	Expressive Helping for Stem Cell Transplant Patients
NCT04951323	PHASE3	UNKNOWN	Impact of the Immune System on Response to Anti-Coronavirus Disease 19 (COVID-19) Vaccine in Allogeneic Stem Cell Recipients (Covid Vaccin Allo)
NCT05158608	PHASE3	UNKNOWN	Comparison of PT-Cy at a Dose of 25 mg/kg/Day and PT-Cy at a Dose of 50 mg/kg/Day in GVHD Prophylaxis
NCT05443854	PHASE3	UNKNOWN	Impact of Aminoglycosides-based Antibiotics Combination and Protective Isolation on Outcomes in Critically-ill Neutropenic Patients With Sepsis: (Combination-Lock01)
NCT05878405	PHASE3	COMPLETED	Methylene Blue Mouthwash for the Treatment of Oral Mucositis Pain in Patients With Cancer
NCT06108739	PHASE3	TERMINATED	ATG Plus Low-dose PT-Cy for GVHD Prevention

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
FILGRASTIM	4	7
FEDRATINIB	4	5
2-MERCAPTOETHANESULFONIC ACID	4	4
ENASIDENIB	4	3
ISATUXIMAB	4	3
PENTOSTATIN	4	3
PLERIXAFOR	4	3
CEFTOLOZANE	4	2
DUVELISIB	4	2
IVOSIDENIB	4	2
MARAVIROC	4	2
MUROMONAB-CD3	4	2
PIPERACILLIN	4	2
PONATINIB	4	2
POSACONAZOLE	4	2
ROMIDEPSIN	4	2
TAGRAXOFUSP	4	2
THIOTEPA	4	2
ALEMTUZUMAB	4	1
ANIDULAFUNGIN	4	1
BELUMOSUDIL	4	1
BENRALIZUMAB	4	1
CABAZITAXEL	4	1
CARFILZOMIB	4	1
CASPOFUNGIN	4	1
CERITINIB	4	1
CHOLECALCIFEROL	4	1
CICLOPIROX	4	1
COBIMETINIB	4	1
COPANLISIB	4	1